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Abstract
Pyruvate dehydrogenase (PDH) catalyzes the conver-
sion of pyruvate to acetyl-coenzyme A, which enters
into the Krebs cycle, providing adenosine triphosphate
(ATP) to the cell. PDH activity is under the control of
pyruvate dehydrogenase kinases (PDKs). Under hyp-
oxic conditions, conversion of pyruvate to lactate
occurs, a reaction catalyzed by lactate dehydrogenase
5 (LDH5). In cancer cells, however, pyruvate is trans-
formed to lactate occurs, regardless of the presence of
oxygen (aerobic glycolysis/Warburg effect). Although
hypoxic intratumoral conditions account for HIF1A
stabilization and induction of anaerobic metabolism,
recent data suggest that high pyruvate concentrations
also result in HIF1A stabilization independently of
hypoxia. In the present immunohistochemical study,
we provide evidence that the PDH/PDK pathway is
repressed in 73% of non small cell lung carcinomas,
which may be a key reason for HIF1A stabilization and
‘‘aerobic glycolysis.’’ However, about half of PDH-
deficient carcinomas are not able to switch on the
HIF pathway, and patients harboring these tumors
have an excellent postoperative outcome. A small
subgroup of clinically aggressive tumors maintains a
coherent PDH and HIF/LDH5 expression. In contrast
to cancer cells, fibroblasts in the tumor-supporting
stroma exhibit an intense PDH but reduced PDK1
expression favoring maximum PDH activity. This
means that stroma may use lactic acid produced by
tumor cells, preventing the creation of an intolerable
intratumoral acidic environment at the same time.
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Introduction
Pyruvate is the end product of glycolysis. Under aerobic
conditions, pyruvate enters the mitochondria, where it is
transformed to acetyl-coenzyme A (acetyl-CoA), produc-
ing dihydronicotinamide adenine dinucleotide (NADH) and
carbon dioxide. Acetyl-CoA subsequently enters into the Krebs
(citric acid) cycle, providing energy (adenosine triphosphate, or
ATP) to the cell. This reaction is catalyzed by the enzyme–
coenzyme complex pyruvate dehydrogenase (PDH) [1]. This
complex is composed of the E2 icosahedral 60-meric core
(digydrolipoamide acetyltransferase) bounded to the E1 pyru-
vate decarboxylase and the E3 dihydrolipoamide dehydroge-
nase components. E3 is held on the E2 core by monomeric
E3-binding proteins (E3BPs) [2–5]. PDH activity is under the
control of pyruvate dehydrogenase kinases (PDKs) 1 to 4,
which phosphorylate the E1 subunit of PDH and suppress
the catalysis of pyruvate to acetyl-CoA [6,7]. The activity of
PDK is regulated by the concentration of the metabolic prod-
ucts of pyruvate (NADH and acetyl-CoA).
Under hypoxic conditions or cell poisoning by inhibitors of
oxidative phosphorylation (i.e., barbiturates, carbon monoxide,
and cyanate), ATP production through glucose conversion to
pyruvate is guaranteed by continuous nicotinamide adenine
dinucleotide (NAD) production following conversion of pyruvate
to lactate, a reaction catalyzed by lactate dehydrogenase
5 (LDH5). This process is called anaerobic glycolysis [8]. In
cancer cells, however, pyruvate is abundantly transformed to
lactate, regardless of the presence of oxygen. This phenome-
non, known historically as the Warburg effect, is called aerobic
glycolysis [9]. The biologic basis of this intensified glycolysis
and shift of pyruvate transformation to lactate in cancer cells
is thought to be related to HIF1a, a key transcription factor
regulating the expression of glycolytic enzymes [10] Although
hypoxic HIF activation does not explain aerobic glycolysis,
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oncogenes can activate this pathway. Recently, Lu et al. [11]
showed that high pyruvate concentrations result in HIF1a
stabilization independently of hypoxia. This could provide
feedback to enhance normoxic induction.
In the present immunohistochemical study, we provide
evidence that the PDH/PDK pathway is repressed in a large
proportion of non small cell lung carcinomas (NSCLCs),
which may contribute to HIF1a stabilization, at least in a
subset of tumors. In contrast to cancer cells, the expres-
sion of PDH/PDHK enzymes was maintained in the fibro-
blasts of the cancer-supporting stroma. In particular, PDH
predominated, suggesting that stroma may have a key
role as a sump to help prevent excess acid accumulation in
the tumor.
Materials and Methods
Tissue samples from 101 surgically resected NSCLCs were
used for investigating the expression of PDH and PDK in
cancer cells and stroma. Autopsy samples from 10 appar-
ently normal lungs were also included. Of these 101 cases,
42 had been previously examined for hypoxic molecular
parameters in relation to prognosis [12–15]. Specimens
had been fixed in formalin and routinely processed to
paraffin wax.
PDH/PDK Immunohistochemistry
Staining for PDH and PDK1 was performed on 3-mm
paraffin sections mounted on poly-L-lysine–coated slides.
The A-213226 and A21325 mouse IgG2a monoclonal anti-
bodies (MoAb) raised against the E2/E3bp and E2 subunits
of human mitochondrial PDH (Molecular Probes, Inc.,
Eugene, OR) were used to detect PDH immunoreactivity.
These MoAbs recognize the presence of the PDH core
protein E2 and the E3-binding protein essential for the
binding of the E3 subunit to E2. This binding seems impor-
tant for the functionality of PDH [5]. Although assessment of
the E1 subunit would also be of interest, it is evident that
absence of E2 or E2/E3BP expression directly reflects low
PDH activity, which was the end point of the present immuno-
histochemical study. The concentration used was 1 mg/ml.
The C-20 goat polyclonal IgG antibody (Santa Cruz Bio-
technology, Santa Cruz, CA) reactive for human PDK1 was
used to stain samples for PDK at a concentration of 1 mg/ml.
A modified streptavidin technique was used for immuno-
histochemistry. Sections were deparaffinized and per-
oxidase was quenched with methanol and H2O2 3% for
15 minutes. Microwaving for antigen retrieval was used
(3 5 minutes). The primary antibodies were applied over-
night. Following washing with TBS, sections were incubated
with a secondary antibody (Kwik Kit, cat. no. 404050;
Thermo Shandon, Pittsburgh, PA) for 15 minutes and
washed in TBS. Kwik streptavidin peroxidase reagent was
applied for 15 minutes and sections were again washed in
TBS. The color was developed by 15-minute incubation with
DAB solution and sections were weakly counterstained with
hematoxylin. Normal lung tissues were used as positive
controls. Normal mouse (for A-213226) or goat (for C-20)
immunoglobulin G was substituted for primary antibodies at
a concentration where immunostaining of control slides gave
a faint cytoplasmic staining.
Other Immunohistochemistry
For forty-two of the tissue samples analyzed for PDH
reactivity, immunohistochemical data regarding hypoxia-
inducible factors (HIFs) 1a and 2a (MoAbs ESEE 122 and
EP190b, respectively; Oxford, UK), carbonic anhydrase-9
(CA9) catalyzing the hydration of carbon dioxide to carbonic
acid (MoAb M75; Prof. J Pastorec, Bratislava, Slovak Re-
public), lactate dehydrogenase-5 (LDH5) (polycloncal Ab
9002; Abcam UK, Cambridge, UK), lactate dehydrogenase-1
(LDH1; polyclonal Ab 9001; Abcam UK), and angiogenesis
(assessment of vascular density using the JC70 anti–CD31
MoAb) were available from previous studies [12–16]. Sur-
vival data were also available for these cases. PDH reac-
tivity was examined in parallel tissue sections cut from the
same tissue blocks used for previous immunohistochemistry
studies. Extensive reports on the methods used for staining,
assessment, and grouping have been previously published
[12–16].
Statistical Analysis
Statistical analyses and graphs were performed using
the GraphPad Prism 4 and the Instat 3.0 packages
(www.graphpad.com; San Diego, CA). The chi-square t-test,
the Fisher’s exact t-test, or the unpaired two-tailed t-test was
used for testing relationships between categorical tumor
variables, as appropriate. Linear regression analysis was
used to test the relationship between continuous variables.
Survival curves were plotted using the method of Kaplan and
Meier, and the log-rank test was used to determine statistical
differences between life tables. All P values are two-sided
and P < .05 was used for significance.
Results and Discussion
Normal Lung PDH/PDK1 Expression
PDH and PDK1 were expressed strongly and consistently
in the cytoplasm of normal bronchial and alveolar cells
(Figure 1, a and b). Immunostaining using the anti-E2 and
anti-E2/E3BP MoAbs showed overlapping results. Linear
regression analysis of the percentage of cells strongly react-
ing for these Abs showed potent statistical correlation
(P < .0001, r = 0.97).
Cancer Cell PDH/PDK Expression
The expression of PDH and PDK1 was examined com-
paratively in a series of 59 (of 101) tissues from NSCLC.
Both enzymes were not expressed in a large proportion of
cancer cells (Figure 1, c and e) and, when expressed, the
staining was weak. In the 59 cases analyzed, the percentage
of cells with strong PDH expression ranged from 0% to 90%
(median 10%). Lack of PDH expression was noted in 29/59
(49%) cases (negative cases), and strong expression in a
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minority (10–40%) of cancer cells (focal or sporadic expres-
sion; Figure 1d ) was noted in 14/59 (24%) cases (classified
as overall weak expression). These results are in full
accordance with previously published studies by Eboli and
Pasquini [17], where PDH levels are dramatically decreased
in skin carcinomas compared to normal epidermis and in
hepatomas compared to normal liver [18]. In our study,
strong expression in more than 50% of cancer cells within
tissue samples was observed in a minority of lung carci-
nomas (16/59; 27%) and these cases were considered as
bearing high PDH reactivity.
PDK1 expression was also reduced in cancer cells (range
0–90%, median 0%). In 34/59 (58%) cases, there was lack
of PDK1 expression (negative expression; Figure 1, f and g),
whereas strong expression of the enzyme in 10% to 40% of
cancer cells was noted in 7/59 (12%) cases (classified as
overall weak expression). In 18/59 (30%) cases, there was
strong PDK expression in > 50% of cancer cells, and these
were considered as bearing high PDK1 reactivity.
Linear regression analysis between the percentage of
cancer cells expressing PDH and PDK revealed a significant
direct association (P < .0001, r = 0.49). Table 1 shows the
categorical analysis of PDH and PDK expression. Low PDH
expression in cancer cells was accompanied by low PDK
expression in the vast majority of cases [27/29 (93%) cases].
In 10/59 (17%) cases, strong PDH/PDK expression was
noted, simulating the patterns of PDH/PDK expression ob-
served in normal lungs. In an additional 6/59 (10%) cases,
PDH activity was maintained, whereas PDK was sup-
pressed. These results show that downregulation of PDH
and PDK is a common event in lung cancer, whereas a
minority (27%) of cases maintain PDH expression.
There was no association of PDH/PDK expression with
TN stage, histology type (squamous cell cancerversus
adenocarcinoma), or histologic differentiation (data not
shown).
Cancer Cell PDH and HIF/LDH5 Expression
Defective PDH/PDK activity in cancer cells, as sug-
gested by the poor PDH/PDK expression in 73% of cases,
would result in an intense accumulation of pyruvate in the
cells and a severe deficit of aerobic acquisition of energy.
Anaerobic pathways of pyruvate metabolism to lactate could
therefore take over for energy acquisition. We therefore
analysed the expression of PDH in a series of 42 NSCLCs
previously extensively examined for various hypoxia/
metabolic parameters. We noted that lack of PDH expression
Figure 1. Expression patterns of PDH and PDK in normal lung and lung cancer. (a) Strong cytoplasmic expression of PDH in normal bronchi (thick arrows) and
adjacent stroma fibroblasts (thin arrows). (b) Intense PDH expression in the alveolar tissue (thick arrows). (c) Lack of PDH expression in a squamous cell lung
carcinoma (thin arrows) adjacent to PDH-positive alveolar tissue (thick arrows). (d) Focal PDH expression in cancer cells (black arrows). (e) Lack of PDH
expression in squamous cell lung cancer (thin arrows) in a background of tumor-supporting stroma exhibiting a strong PDH reactivity (thick arrows). Strong
expression of PDK in cancer cells (thin arrows) of a squamous cell carcinoma (f) and adenocarcinoma (g). Note the repression of PDK in the tumor-supporting
stroma (thick arrows).
Table 1. Association of PDH Reactivity with the Expression of PDK (n = 59).
PDK PDH P
Negative Weak High
Negative 22 6 6 .001
Weak 5 2 0
High 2 6 10
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was associated with HIF1a stabilization and/or LDH5 over-
expression in about half of PDH-deficient tumors, (Table 2).
Because of shortage of material and close association of
PDH with PDK, as shown above, PDK was not analysed in
this group.
LDH5 gene is transcriptionally regulated by HIF1a [19]
and, indeed, in a recent study, we noted a direct association
of HIF1a and LDH5 expression in NSCLC [14]. In a recent
experimental study, high pyruvate concentration induced
HIF1a stabilization, independently of hypoxia [11]. It is
plausible that in PDH-deficient tumors, HIF1a/LDH5 up-
regulation is a consequence of pyruvate accumulation. Such
an effect would allow the acquisition of energy through
pyruvate reduction to lactate. This, however, concerns about
half of PDH-deficient tumors, as 15/31 and 18/31 of such
tumors seemed not to switch on HIF1a and/or LDH5, respec-
tively. These later category of tumors, with an apparent
defective pyruvate metabolism (in both citric acid and lactate
production directions), were linked with an excellent post-
operative outcome in a series of 42 patients analyzed, for
which survival data were available (Figure 2).
Of interest, a direct association of high PDH expression
with HIF1a and LDH5 expression was noted, as all cases
maintaining normal PDH reactivity had also high HIF1a and
LDH5 expression. It would have been expected that intense
PDH activity and metabolism of pyruvate to acetyl-CoA
would compete for pyruvate and reduce pools that directly
regulate HIF. These cases may therefore maintain HIF by
hypoxia- or oncogene-mediated pathways. In any case,
tumors able to generate energy by aerobic and anaerobic
pathways may have an advantage in growth. However,
preservation of the E2 subunit does not necessarily predict
for PDH functionality as additional factors, such as PDK
overexpression, may suppress PDH activity, and these
cases may in fact bear an impaired aerobic metabolism.
In a previous study, we showed that, in contrast to
LDH5, LDH1 is expressed consistently in all normal tissues.
This expression is maintained or lost during neoplastic trans-
formation, whereas LDH5 is expressed preferentially in tumor
cells [16]. The cellular population of the tumor-supporting
stroma shows consistent LDH1 reactivity and LDH5 activity
in a small percentage of cases (in cases with stroma HIF1a
reactivity). LDH1 is less efficient than LDH5 in catalyzing the
conversion of pyruvate to lactate, and favors the conversion
of pyruvate to acetyl-CoA that enters into the citric acid
(Krebs) cycle. In the present study, no association of LDH1
with PDH and PDK1 was noted in cancer cells. The
consistent LDH1 expression in the tumor-related stroma
goes along with the strong PDH expression, further support-
ing the suggestion that tumoral stroma maintains strong
aerobic metabolism.
PDH/HIF/LDH5 Expression and Tumor Vasculature
Analysis of VD showed no differences between PDH/
HIF1a (or PDH/LDH5)–positive tumors and the remaining
of tumors (data not shown). In a previous study [20], we
proposed a classification of lung carcinoma vascularity
according to the ability of tumors to sustain inner vascula-
ture. High tumor angiogenic activity as assessed at the
tumor invading edge was not always followed by high inner
vascular density, so that highly angiogenic tumors were
divided in two groups of low and high vascular survival ability
(edvin scores 2 and 3, respectively; edvin: edge versus
inner). Tumors with low angiogenic activity at the invading
edge were classified as edvin 1. Analysis of the PDH/HIF
phenotype according to the edvin score showed that tumors
with simultaneously intensified PDH and HIF/LDH5 path-
ways were mainly of edvin 3 score, thus were tumors with
high angiogenic activity and high vascular survival ability
Table 2. Association of PDH Expression with HIF1a and HIF2a, LDH5, and




Low 15 0 .003
High 16 11
HIF2a
Low 15 3 .29
High 16 8
LDH5
Low 18 0 .0008
High 13 11
CA9
Low 17 7 .79
High 14 4
Figure 2. Kaplan-Meier overall survival curves according to PDH expression,
stratified for HIF1a (a) and LDH5 expression (b) (n = 42). Note that cases with
contemporaneous defective metabolism in both aerobic (low PDH expres-
sion) and anaerobic (low HIF1a or low LDH5) directions had a particularly
favorable outcome.
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(tumors with dense vasculature throughout the tumoral
mass) (Table 3). It seems, therefore, that this subgroup of
tumors is less likely to be hypoxic. So concurrent PDH and
HIF1/LDH5 upregulation could occur due to genetic events
that switch on the entire cellular metabolism. Such tumors
with intensively upregulated aerobic and anaerobic meta-
bolic potential were linked with particularly poor prognosis
(Figure 2, a and b). It should be, however, kept in mind that
expression of the E2 subunit does not guarantee PDH
functionality, and that HIF1 overexpression in this latter
group may still be a cause of PDH inactivity.
PDH/PDK Expression in Cancer Cells Versus
Tumoral Stroma
Normal lung stroma fibroblasts were positive for both
PDH and PDK1. Results for the tumor stroma fibroblasts
showed a major difference for PDK1. Despite the intense
overall downregulation of PDH in cancer cells, fibroblasts in
the tumor-supporting stroma maintained an intense PDH
expression (Figure 1d ). This shows that tumoral stroma
maintains a high ability for aerobic pyruvate consumption.
HIF and LDH5 expression in tumor fibroblasts is only excep-
tionally present, whereas LDH1 isoenzyme (favoring aerobic
metabolism of pyruvate) is strongly expressed as previously
reported [14,16].
However, PDK1 expression was impressively down-
regulated in stroma fibroblasts compared to normal lung
(Figure 1e), suggesting that PDH activity was further facili-
tated by inactivation of the PDK-mediated negative regula-
tion on PDH. Although additional studies are required to
assess whether PDK2, PDK3, and PDK4 are also down-
regulated in the tumor-related stroma, the confirmation of
PDK1 suppression is important as preliminary data show that
PDK1, in contrast to PDK2 and PDK3, is not hypoxia-
regulated (unpublished data). It is suggested that PDK1
suppression in the tumor-related stroma is a result of a
paracrine tumor/fibroblast interaction and not a hypoxia-
related effect. These observations strongly suggest that
stroma fibroblasts maintain an exclusively aerobic metabo-
lism of pyruvate, preventing lactate formation from glucose.
This metabolic preference by the tumor-supporting stroma
could be a consequence of the high concentration of lactic
acid produced and extruded out of cancer cells, and could be
very useful for tumor survival to avoid self-destruction by
excessive acidosis. If tumor stroma, apart from providing a
structural skeleton, also provides buffering and metabolic
support to cancer cells, then drugs targeting the specific
features of the cancer-supporting stroma metabolism may
prove antitumorigenic and tumoricidal, which deserves fur-
ther investigation.
Conclusions
It is concluded that the majority of NSCLCs has a metabolic
deficit in the PDH expression regulation, the molecular basis
of which remains to be elucidated. Pyruvate intracellular
accumulation (due to intensively activated glycolytic path-
ways) [10,11] in the context of PDH downregulation, and not
hypoxia, may be an important factor for HIF1a stabilization,
with LDH5 overexpression and shift of the pyruvate metabo-
lism to lactate production. Defective PDH regulation may
be part of the explanation of cancer cell–specific ‘‘aerobic
glycolysis’’ phenomenon noted by Warburg [9]. However, a
large percentage of PDH-deficient carcinomas (50%) is not
able to switch on the HIF pathway and these tumors are
linked with an excellent postoperative outcome. A subgroup
of tumors (about 20% of NSCLC) shows a coherent intense
PDH and HIF/LDH5 presence, therefore sharing strong
aerobic and anaerobic metabolic abilities. Such tumors are
endowed with a particularly aggressive behaviour, which
leads to poor postoperative outcome. The biologic signifi-
cance of the fact that tumoral stroma, in contrast to cancer
cells, maintains a strictly aerobic metabolism with the likeli-
hood of maximal PDH function due to downregulation of
inhibitory kinase should be further studied as a mechanism
by which tumors deal with their acid load.
References
[1] Harris RA, Bowker-Kinley MM, Hyang B, and Wu P (2002). Regulation
of the activity of the pyruvate dehydrogenase complex. Adv Enzyme
Regul 42, 2249–2259.
[2] Reed LJ and Hackert ML (1990). Structure– function relationships in
dihydrolipoamide acyltransferases. J Biol Chem 265, 8971–8974.
[3] Sanderson SJ, Miller C, and Lindsay JG (1996). Stoichiometry, organi-
sation and catalytic function of protein X of the pyruvate dehydrogenase
complex from bovine heart. Eur J Biochem 236, 68–77.
[4] Maeng CY, Yazdi MA, Niu XD, Lee HY, and Reed LJ (1994). Expres-
sion, purification, and characterization of the dihydrolipoamide dehydro-
genase-binding protein of the pyruvate dehydrogenase complex from
Saccharomyces cerevisiae. Biochemistry 33, 13801–13807.
[5] Harris RA, Bowker-Kinley MM, Wu P, Jeng J, and Popov KM (1997).
Dihydrolipoamide dehydrogenase–binding protein of the human pyru-
vate dehydrogenase complex. DNA-derived amino acid sequence, ex-
pression, and reconstitution of the pyruvate dehydrogenase complex.
J Biol Chem 272, 19746–19751.
[6] Harris RA, Huang B, and Wu P (2001). Control of pyruvate dehydrogen-
ase kinase gene expression. Adv Enzyme Regul 41, 269–288.
[7] Sugden MC and Holness MJ (2003). Recent advances in mechanisms
regulating glucose oxidation at the level of the pyruvate dehydrogenase
complex by PDKs. Am J Physiol Endocrinol Metab 284, 855–862.
[8] Holbrook JJ, Liljas A, Steindel SJ, and Rossman MG (1975). In
Boyer, PD (Ed.), 3rd ed. Lactate dehydrogenase: Vol XI.The En-
zymes, pp. 191–292 Academic Press, New York.
[9] Warburg O (1956). On the origin of cancer cells. Science 123 (391),
309–314.
[10] Semenza GL, Roth PH, Fang HM, and Wang GL (1994). Transcrip-
tional regulation of genes encoding glycolytic enzymes by hypoxia-
inducible factor 1. J Biol Chem 269, 23757–23763.
[11] Lu H, Forbes RA, and Verma A (2002). Hypoxia-inducible factor 1
activation by aerobic glycolysis implicates the Warburg effect in car-
cinogenesis. J Biol Chem 277, 23111–23115.
Table 3. Edvin Patterns of Vascularisation According to the PDH/HIF and
PDH/LDH5 Expression Profile.
PDH/HIF1a PDH/LDH5
Low/Low Low/High High/High Low/Low Low/High High/High
Edvin
1 7 8 2 10 5 2
2 6 4 2 6 4 2
3 2 4 7 2 4 7
P = .07* and .01y P = .06* and .01y
*Edvin 1 vs. 2 vs. 3 (chi-square analysis).
yEdvin 1/2 vs. 3 (Fisher’s exact test).
PDH/PDK in Lung Cancer Koukourakis et al. 5
Neoplasia . Vol. 7, No. 1, 2005
[12] Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K,
Pezzella F, Gatter KC, and Harris AL (2001). Relation of hypoxia-
inducible factor 1 alpha and 2 alpha in operable non-small cell lung
cancer to angiogenic/molecular profile of tumours and survival. Br J
Cancer 85, 881–890.
[13] Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC,
Gatter KC, and Harris AL (2001). Expression of hypoxia-inducible car-
bonic anhydrase-9 relates to angiogenic pathways and independently to
poor outcome in non-small cell lung cancer.CancerRes 61, 7992–7998.
[14] Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V,
Gatter KC, Harris AL,Tumour and Angiogenesis Research Group
(2003). Lactate dehydrogenase-5 (LDH-5) overexpression in non-
small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic
factor production and poor prognosis. Br J Cancer 89, 877–885.
[15] Giatromanolaki A, Koukourakis M, O’Byrne K, Fox S, Whitehouse R,
Talbot D, Harris AL, and Gatter KC (1996). Prognostic value of angio-
genesis in operable non-small cell lung cancer. J Pathol 179, 80–88.
[16] Koukourakis MI, Giatromanolaki A, and Sivridis E (2003). Lactate de-
hydrogenase (LDH) isoenzymes 1 and 5 expression by neoplastic and
stromal cells in non-small cell lung cancer and other epithelial malignant
tumors. Tumor Biol 24, 199–202.
[17] Eboli ML and Pasquini A (1994). Transformation linked decrease of
pyruvate dehydrogenase complex in human epidermis. Cancer Lett
85, 239–243.
[18] Eboli ML (1985). Pyruvate dehydrogenase levels in Morris hepatomas
with different growth rate. Cancer Lett 26, 185–190.
[19] Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP,
Maire P, and Giallongo A (1996). Hypoxia response elements in the
A aldolase, enolase 1, and lactate dehydrogenase A gene promoters
contain essential binding sites for hypoxia-inducible factor 1. J Biol
Chem 271, 32529–32537.
[20] Giatromanolaki A, Koukourakis MI, Sivridis E, O’Byrne K, Gatter KC,
and Harris AL (2000). ‘‘Invading edge vs inner’’ (edvin) patterns of
vascularization: an interplay between angiogenic and vascular survival
factors defines the clinical behaviour of non-small cell lung cancer.
J Pathol 192, 140–149.
6 PDH/PDK in Lung Cancer Koukourakis et al.
Neoplasia . Vol. 7, No. 1, 2005
